Naprosyn
PreclinicalSmall molecule
Naprosyn is one of 9 small molecule programs targeting Multimodal Analgesia. It is currently in Preclinical.
1
Indications
7
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Multimodal Analgesia
#DrugCompanyPhaseTrials
1Neurontin
VViatris Specialty LLC
Approved
Tylenol
KKenvue Brands
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Acupan
YYonsei University
Preclinical
Valium
Akero TherapeuticsPreclinical
Dexketoprofen Trometamol
MenariniPreclinical
Celebrex
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Imovane
TTaisho Pharmaceutical Co., Ltd.
Preclinical
Naprosyn
LLogical Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteoarthritis1 trial
Medication1 trial
2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Naprosyn. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- LLogical Therapeutics